Activation of peroxisome proliferator-activated receptor-γ downregulates soluble epoxide hydrolase in cardiomyocytes (Q39598383)

13 September 2017

Activation of peroxisome proliferator-activated receptor-γ downregulates soluble epoxide hydrolase in cardiomyocytes (English)

1 reference

Soluble epoxide hydrolase

13 September 2017

0 references

author name string

Wei Pang

1

1 reference

13 September 2017

Nan Li

2

1 reference

13 September 2017

Ding Ai

3

1 reference

13 September 2017

Xiao-Lin Niu

4

1 reference

13 September 2017

You-Fei Guan

5

1 reference

13 September 2017

Yi Zhu

6

1 reference

13 September 2017

1 June 2011

1 reference

Clinical and Experimental Pharmacology and Physiology

13 September 2017

1 reference

13 September 2017

38

1 reference

13 September 2017

6

1 reference

13 September 2017

358-364

1 reference

Assessment of the coronary artery disease and systolic dysfunction in hypertensive patients with the dobutamine-atropine stress echocardiography: effect of the left ventricular hypertrophy.

13 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Stress pathways and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

P-450 metabolites of arachidonic acid in the control of cardiovascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Epoxygenase pathways of arachidonic acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Myocardial reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Peroxisome proliferator-activated receptors in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Generation and functional confirmation of a conditional null PPARgamma allele in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Peroxisome proliferator-activated receptor γ in diabetes and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

The role of PPARgamma-dependent pathway in the development of cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

DNA methylation of the promoter of soluble epoxide hydrolase silences its expression by an SP-1-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05492.X

10.1111/J.1440-1681.2011.05492.X

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference